• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.

作者信息

Hengeveld P J, Schilperoord-Vermeulen J, van der Klift M Y, Dubois J M N, Kolijn P M, Kavelaars F G, Rijken M, Dobber J A, Nasserinejad K, Kersting S, Westerweel P E, Kater A P, Langerak A W, Levin M-D

机构信息

Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.

Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.

出版信息

Blood Cancer J. 2023 Jul 4;13(1):102. doi: 10.1038/s41408-023-00870-2.

DOI:10.1038/s41408-023-00870-2
PMID:37400508
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10317999/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c6e/10317999/d639955fd0c0/41408_2023_870_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c6e/10317999/503c52c0ab24/41408_2023_870_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c6e/10317999/d639955fd0c0/41408_2023_870_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c6e/10317999/503c52c0ab24/41408_2023_870_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c6e/10317999/d639955fd0c0/41408_2023_870_Fig2_HTML.jpg

相似文献

1
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.慢性淋巴细胞白血病患者在接受维奈克拉和奥妥珠单抗治疗期间的早期可测量残留病动态及IGHV基因库重建
Blood Cancer J. 2023 Jul 4;13(1):102. doi: 10.1038/s41408-023-00870-2.
2
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.在初治的TP53基因异常的慢性淋巴细胞白血病患者中持续使用维奈托克：一项慢性淋巴细胞白血病领域研究
Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29.
3
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.美国接受维奈托克治疗的慢性淋巴细胞白血病患者的真实世界结局和管理策略。
Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.
4
[Current diagnosis and treatment of chronic lymphocytic leukaemia].[慢性淋巴细胞白血病的当前诊断与治疗]
Dtsch Med Wochenschr. 2020 Aug;145(16):1139-1144. doi: 10.1055/a-1039-8472. Epub 2020 Aug 13.
5
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.维奈托克联合奥滨尤妥珠单抗治疗复杂核型慢性淋巴细胞白血病患者疗效显著。
Blood. 2020 Mar 12;135(11):866-870. doi: 10.1182/blood.2019003451.
6
Pairing obinutuzumab with venetoclax in relapsed CLL.在复发的慢性淋巴细胞白血病中，将奥妥珠单抗与维奈克拉联合使用。
Leuk Lymphoma. 2024 May;65(5):543-545. doi: 10.1080/10428194.2024.2323682. Epub 2024 Mar 18.
7
Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia.维奈托克：初治慢性淋巴细胞白血病的治疗药物。
Drugs. 2020 Dec;80(18):1973-1980. doi: 10.1007/s40265-020-01433-6.
8
An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.维奈托克和奥滨尤妥珠单抗在慢性淋巴细胞白血病中的更新。
Future Oncol. 2021 Feb;17(4):371-387. doi: 10.2217/fon-2020-0640. Epub 2020 Oct 16.
9
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.维奈托克与奥妥珠单抗治疗慢性淋巴细胞白血病
Blood. 2017 May 11;129(19):2702-2705. doi: 10.1182/blood-2017-01-761973. Epub 2017 Mar 21.
10
Emerging data for venetoclax in chronic lymphocytic leukemia.
Clin Adv Hematol Oncol. 2022 Mar;20(3):178-183.

引用本文的文献

1
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients.使用奥妥珠单抗加维奈克拉治疗可重塑慢性淋巴细胞白血病患者的T细胞受体β链库。
Blood Cancer J. 2025 Jan 7;15(1):2. doi: 10.1038/s41408-025-01209-9.

本文引用的文献

1
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.通过基于 IGHV 先导区的 NGS 方法检测到超过 10-4 的可测量残留疾病可改善 CLL 的预后分层。
Blood. 2023 Feb 2;141(5):519-528. doi: 10.1182/blood.2022017411.
2
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.在固定疗程 venetoclax-rituximab 治疗后缓解/难治性 CLL 患者中持续不可检测的微小残留病和更新的结果。
Blood. 2022 Aug 25;140(8):839-850. doi: 10.1182/blood.2021015014.
3
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
维奈托克联合奥滨尤妥珠单抗固定疗程治疗初治慢性淋巴细胞白血病（HOVON 139/GiVe）：多中心、开放标签、随机、平行分组、2 期临床试验的主要终点分析。
Lancet Haematol. 2022 Mar;9(3):e190-e199. doi: 10.1016/S2352-3026(22)00034-5.
4
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.泽布替尼、奥滨尤妥珠单抗和维奈托克联合治疗慢性淋巴细胞白血病或小淋巴细胞淋巴瘤初治患者：基于微小残留病灶驱动停药的多中心、单臂、2 期临床试验。
Lancet Haematol. 2021 Dec;8(12):e879-e890. doi: 10.1016/S2352-3026(21)00307-0.
5
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.维奈托克联合奥滨尤妥珠单抗治疗后的微小残留病动态：来自随机 CLL14 研究的延长治疗后随访。
J Clin Oncol. 2021 Dec 20;39(36):4049-4060. doi: 10.1200/JCO.21.01181. Epub 2021 Oct 28.
6
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?慢性淋巴细胞白血病中的微小残留病：一个新目标？
Front Oncol. 2019 Aug 29;9:689. doi: 10.3389/fonc.2019.00689. eCollection 2019.
7
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.伊布替尼联合维奈托克治疗复发/难治性慢性淋巴细胞白血病：CLARITY 研究。
J Clin Oncol. 2019 Oct 20;37(30):2722-2729. doi: 10.1200/JCO.19.00894. Epub 2019 Jul 11.
8
Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis.在健康受试者中基于模型的 Venetoclax 剂量调整：暴露-反应分析。
Clin Transl Sci. 2019 Nov;12(6):625-632. doi: 10.1111/cts.12665. Epub 2019 Aug 7.
9
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.伴有合并症的慢性淋巴细胞白血病患者接受苯丁酸氮芥联合奥滨尤妥珠单抗或利妥昔单抗治疗后微小残留病灶的预后价值。
Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19.